|
|
A randomized controlledtrial about the treatment of first-episode depression by agomelatine and escitalopram |
LI Huijing1, CUI Minghu2 ZHANG Lanlan2, SUN Guizhi2, WU Xiaorui2, GE Xiangli1 |
1 School of Clinical Medicine, Binzhou Medical University, Yantai 264003, P.R.China; 2 Department of Psychology, Binzhou Medical University Hospital |
|
|
Abstract Objective To explore the clinical efficacy and safety of agomelatine and escitalopram used for the treatment of first-episode depression. Methods Sixty patients with first-episode depression were randomly divided into the research group and control group, and each group had 30 patients. The control group was treated with escitalopram, and the research group was treated with agomelatine for 8 weeks. The Hamilton depression rating scale-17 (HAMD-17) and side effect scale (TESS) were used to evaluate the clinical efficacy and adverse reactions. The difference of clinical efficacy was compared according to HAMD-17 scores of two groups and the difference of adverse reactions was compared according to TESS scores of two groups. Results There was no statistically significant difference between the HAMD-17 scores of control group after treatment of 1 week and that before the treatment. The differences among the HAMD-17 scores of control group after treatment of 2, 4, 8 weeks and that before the treatment were significant. The differences were significant among the HAMD-17 scores of research group after treatment and that before the treatment. Conclusion The effect of escitalopram was better than that of agomelatine after treatment of 4 weeks. With the extension of time, the effect between escitalopram and agomelatine was similar after treatment of 8 weeks, but agomelatine had a rapid onset of effect, around 1 week, and escitalopram needs 2 weeks. Both drugs had fewer adverse reactions and higher safety.
|
Received: 27 February 2019
|
|
|
|
|
[1] Kessler R C, Berlund P, Demler O, et al.The epidemiology of major depressive disorder: results for the National Comorbidity Survey Replication (NCS-R) [J]. JAMA, 2003, 289(23): 3095-3105. [2] De Bodinat C, Guardiola Lemaitre B, Mocaer E, et al. Agomelatine, the first melatonergic antidepressant: discovery characterization and development[J]. Nat RevDrug Discov, 2010, 9(8): 628-642. [3] Phillips M R, Zhang J, Shi Q, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey [J]. Lancet, 2009, 373(9680): 2041-2053. [4] Mayberg H S, Lozano A M, Voon V, et al. Deep brain stimulation for treatment-resistant depression[J]. Neuron, 2005, 45(5): 651-660. [5] Quera-Salva M A, Hajak G, Philip P, et al.Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients [J]. Int Clin Psychopharmacol, 2011, 26(5):252-262. [6] Hale A, Corral R M, Mencacci C, et al.Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized,double-blind study[J]. Int Clin Psychopharmacol, 2010, 25(6):305-314. [7] 戴雯姬, 司天梅. 阿戈美拉汀的药理机制及临床疗效 [J]. 中国心理卫生杂志, 2012, 26(3): 193-198. [8] tuhec M. Agomelatine-induced hepatotoxicity [J]. Wien Klin Wochenschr, 2013,125(7):225-226. [9] 沈渔邨. 精神病学[M]. 5版.北京:人民卫生出版社, 2014: 880-898. |
[1] |
KONG Lingchen, SUN Yunbo, XU Jianhua, PENG Wenhong, LU Shijun, NING Chao, LI Haiyan. Effect of lung recruitment maneuver and protective ventilation on postoperative acute respiratory distress syndrome[J]. 滨州医学院学报, 2019, 42(5): 323-327. |
[2] |
GUO Lantian, MA Zhenzhen, FENG Yan, ZOU Xuexue. Logistic regression analysis about the diagnostic value of multisliecs helieal CT on thyroid benign and malignant nodules[J]. 滨州医学院学报, 2019, 42(5): 342-345. |
[3] |
MA Dejing, LU Feng, ZHANG Hu, DONG Jingmin, MA Mimi. Correlation analysis among parameters of IVIM-DWI model, prognostic factors and molecular subtypes of breast cancer[J]. 滨州医学院学报, 2019, 42(5): 349-352. |
[4] |
FENG Dexiang, WEI Xiuhong, LUAN Shunlian, KONG Dehai. Researchabout the nursing needs of the rural elderly in Binzhou[J]. 滨州医学院学报, 2019, 42(5): 360-362. |
[5] |
HE Xiaomin, JIA Zhihui, ZHAO Yongjun, LIU Jingyu, DU Qing. Analysis of the requirements of family doctor contract service in a city community[J]. 滨州医学院学报, 2019, 42(5): 357-359. |
|
|
|
|